keyword
https://read.qxmd.com/read/37112961/mechanisms-of-action-of-the-host-targeting-agent-cyclosporin-a-and-direct-acting-antiviral-agents-against-hepatitis-c-virus
#21
JOURNAL ARTICLE
Dandan Liu, Tanya P Ndongwe, Juan Ji, Andrew D Huber, Eleftherios Michailidis, Charles M Rice, Robert Ralston, Philip R Tedbury, Stefan G Sarafianos
Several direct-acting antivirals (DAAs) are available, providing interferon-free strategies for a hepatitis C cure. In contrast to DAAs, host-targeting agents (HTAs) interfere with host cellular factors that are essential in the viral replication cycle; as host genes, they are less likely to rapidly mutate under drug pressure, thus potentially exhibiting a high barrier to resistance, in addition to distinct mechanisms of action. We compared the effects of cyclosporin A (CsA), a HTA that targets cyclophilin A (CypA), to DAAs, including inhibitors of nonstructural protein 5A (NS5A), NS3/4A, and NS5B, in Huh7...
April 17, 2023: Viruses
https://read.qxmd.com/read/36920600/hepatitis-c-virus-nonstructural-protein-4b-induces-lipogenesis-via-the-hippo-pathway
#22
JOURNAL ARTICLE
Chen Zou, Hongxi Tan, Jun Zeng, Minqi Liu, Guangping Zhang, Yi Zheng, Zhanfeng Zhang
Hepatitis C virus (HCV) infection causes abnormal lipid metabolism in hepatocytes, which leads to hepatic steatosis and even hepatocellular carcinoma. HCV nonstructural protein 4B (NS4B) has been reported to induce lipogenesis, but the underlying mechanism is unclear. In this study, western blots were performed to investigate the effect of NS4B protein levels on key effectors of the Hippo and AKT signaling pathways. Yes-associated protein (YAP) and moesin-ezrin-radixin-like protein (Merlin) are effectors of the Hippo pathway...
March 15, 2023: Archives of Virology
https://read.qxmd.com/read/36822034/nonstructural-protein-2a2-from-duck-hepatitis-a-virus-type-1-inhibits-interferon-beta-production-by-interaction-with-mitochondrial-antiviral-signaling-protein-and-tank-binding-kinase-1
#23
JOURNAL ARTICLE
Nana Sui, Ruihua Zhang, Yue Jiang, Honglei Yu, Guige Xu, Jingyu Wang, Yanli Zhu, Zhijing Xie, Jiaqing Hu, Shijin Jiang
Type I interferon (IFN-I) is essential for the regulation of host-virus interactions, and viruses have evolved strategies to escape the host immune response. Duck hepatitis A virus type 1 (DHAV-1) causes severe liver necrosis and hemorrhage, neurological symptoms, and high mortality in ducklings. However, how DHAV-1 interacts with the duck innate immune system remains unclear. In this study, DHAV-1-encoded proteins were cloned, and DHAV-1 2A2 was shown to strongly suppress IFN-β-luciferase activity, triggered by Sendai virus and polyriboinosinic polyribocytidylic acid [poly(I:C)], along with the transcription of IFN-β and downstream antiviral genes, including OASL, PKR, and TNF-a...
February 10, 2023: Veterinary Microbiology
https://read.qxmd.com/read/36595855/a-rare-case-report-of-iatrogenic-cushing-syndrome-caused-by-direct-anti-hepatitis-c-virus-therapy-with-sofosbuvir-velpatasvir
#24
JOURNAL ARTICLE
Bo Ma, Tianling Shang, Jianjie Huang, Zhixin Tu, Yan Wang, Yujin Han, Yang Wang, Xiaoyu Wen, Qinglong Jin
RATIONALE: Sofosbuvir/velpatasvir (SOF/VEL) is a combination of direct-acting antivirals with pan-genotypic activity that is used to treat chronic hepatitis C virus infection. This was a fixed-dose regimen. SOF is a nucleotide nonstructural 5B polymerase inhibitor and VEL is an nonstructural 5A inhibitor. Side effects of this agent on the endocrine system, particularly iatrogenic Cushing syndrome (ICS), are uncommon. Here, we present a case of ICS with significantly low serum adrenocorticotropic hormone and cortisol levels caused by SOF/VEL...
December 23, 2022: Medicine (Baltimore)
https://read.qxmd.com/read/36323770/discovery-of-sars-cov-2-antiviral-synergy-between-remdesivir-and-approved-drugs-in-human-lung-cells
#25
JOURNAL ARTICLE
Xammy Nguyenla, Eddie Wehri, Erik Van Dis, Scott B Biering, Livia H Yamashiro, Chi Zhu, Julien Stroumza, Claire Dugast-Darzacq, Thomas G W Graham, Xuanting Wang, Steffen Jockusch, Chuanjuan Tao, Minchen Chien, Wei Xie, Dinshaw J Patel, Cindy Meyer, Aitor Garzia, Thomas Tuschl, James J Russo, Jingyue Ju, Anders M Näär, Sarah Stanley, Julia Schaletzky
SARS coronavirus 2 (SARS-CoV-2) has caused an ongoing global pandemic with significant mortality and morbidity. At this time, the only FDA-approved therapeutic for COVID-19 is remdesivir, a broad-spectrum antiviral nucleoside analog. Efficacy is only moderate, and improved treatment strategies are urgently needed. To accomplish this goal, we devised a strategy to identify compounds that act synergistically with remdesivir in preventing SARS-CoV-2 replication. We conducted combinatorial high-throughput screening in the presence of submaximal remdesivir concentrations, using a human lung epithelial cell line infected with a clinical isolate of SARS-CoV-2...
November 2, 2022: Scientific Reports
https://read.qxmd.com/read/36193545/rna-dependent-rna-polymerase-rdrp-natural-antiviral-inhibitors-a-review
#26
REVIEW
Daniela Regina Buch Leite, Karen Mary Mantovani, Solange Pereira Cordeiro, Filipe Barros Maia, Fernando Cesar Martins Betim, Elisiane de Bona Sartor, Deise Prehs Montrucchio, Josiane de Fátima Gaspari Dias, Obdulio Gomes Miguel, Marilis Dallarmi Miguel
Viral diseases are the cause of many global epidemics, leading to deaths, affecting the quality of life of populations, and impairing public health. The limitations in the treatment of viral diseases and the constant resistance to conventional antiviral treatments encourage researchers to discover new compounds. In this perspective, this literature review presents isolated molecules and extracts of natural products capable of inhibiting the activity of the nonstructural protein that acts as the RNA-dependent RNA polymerase...
September 29, 2022: Medicinal Chemistry Research
https://read.qxmd.com/read/36072891/independent-evolution-of-multi-dominant-viral-genome-species-observed-in-a-hepatitis-c-virus-carrier
#27
JOURNAL ARTICLE
Tomomi Ando, Hideki Aizaki, Masaya Sugiyama, Tomoko Date, Kazuhiko Hayashi, Masatoshi Ishigami, Yoshiaki Katano, Hidemi Goto, Masashi Mizokami, Masamichi Muramatsu, Makoto Kuroda, Takaji Wakita
The viral genome quasispecies composition of hepatitis C virus (HCV) could have important implications to viral pathogenesis and resistance to anti-viral treatment. The purpose of the present study was to profile the HCV RNA quasispecies. We developed a strategy to determine the full-length HCV genome sequences co-existing within a single patient serum by using next-generation sequencing technologies. The isolated viral clones were divided into the groups that can be distinguished by core amino acid 70 substitution...
December 2022: Biochemistry and Biophysics Reports
https://read.qxmd.com/read/36053294/in-silico-positional-analogue-scanning-with-amber-gpu-ti
#28
JOURNAL ARTICLE
Yuan Hu, Ingo Muegge
Positional analogue scanning (PAS) is an accepted strategy for multiparameter lead optimization (MPO) in drug discovery. Small structural changes as introduced by PAS can lead to 10-fold changes in binding potency in ∼10-20% of cases, a significant parameter shift irrespective of other MPO objectives. Sometimes performing a complete PAS is challenging due to resource and time constraints, building block availability, or difficulty in synthesis. Calculating relative binding free energies (RBFEs) for all positions can contribute to prioritizing the most promising analogues for synthesis...
September 2, 2022: Journal of Chemical Information and Modeling
https://read.qxmd.com/read/36040967/design-of-a-novel-multi-epitope-vaccine-candidate-against-hepatitis-c-virus-using-structural-and-nonstructural-proteins-an-immunoinformatics-approach
#29
JOURNAL ARTICLE
Esmaeil Behmard, Hussein T Abdulabbas, Saade Abdalkareem Jasim, Sohrab Najafipour, Abdolmajid Ghasemian, Akbar Farjadfar, Ebrahim Barzegari, Amin Kouhpayeh, Parviz Abdolmaleki
Hepatitis C virus (HCV) infects the liver and causes chronic infection. Several mutations in the viral genome have been associated with drug resistance development. Currently, there is no approved vaccine against the HCV. The employment of computational biology is the primary and crucial step for vaccine design or antiviral therapy which can substantially reduce the duration and cost of studies. Therefore, in this study, we designed a multi-epitope vaccine using various immunoinformatics tools to elicit the efficient human immune responses against the HCV...
2022: PloS One
https://read.qxmd.com/read/36002650/partial-nonstructural-3-region-analysis-of-hepatitis-c-virus-genotype-3a
#30
JOURNAL ARTICLE
Anusorn Kiattanaphon, Yaovaluk Vipsoongnern, Duangkamol Kunthalert, Anchalee Sistayanarain
BACKGROUND: The hepatitis C virus (HCV) is a major cause of illness around the world. HCV genotype 3a is the most prevalent genotype in Thailand. Direct-acting antiviral (DAA) drugs are available for treatment, and these drugs target the NS3, NS5A, and NS5b proteins of HCV. However, HCV variants that are resistant to NS3 protease inhibitors have been found during treatment. This resistance can be naturally occurring or in response to treatment. The purpose of this study is to analyze the codon positions of the main mutation of the partial NS3 gene region of HCV genotype 3a...
August 24, 2022: Molecular Biology Reports
https://read.qxmd.com/read/35993162/hepatitis-c-virus-nonstructural-protein-5a-interacts-with-immunomodulatory-kinase-ikk%C3%AE%C2%B5-to-negatively-regulate-innate-antiviral-immunity
#31
JOURNAL ARTICLE
Sang-Min Kang, Ji-Young Park, Hee-Jeong Han, Byeong-Min Song, Dongseob Tark, Byeong-Sun Choi, Soon B Hwang
Hepatitis C virus (HCV) infection can lead to chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. HCV employs diverse strategies to evade host antiviral innate immune responses to mediate a persistent infection. In the present study, we show that nonstructural protein 5A (NS5A) interacts with an NF-κB inhibitor immunomodulatory kinase, IKKε, and subsequently downregulats beta interferon (IFN-β) promoter activity. We further demonstrate that NS5A inhibits DDX3-mediated IKKε and interferon regulatory factor 3 (IRF3) phosphorylation...
August 22, 2022: Molecules and Cells
https://read.qxmd.com/read/35947700/biochemical-and-structural-characterization-of-hepatitis-a-virus-2c-reveals-an-unusual-ribonuclease-activity-on-single-stranded-rna
#32
JOURNAL ARTICLE
Pu Chen, Justyna Aleksandra Wojdyla, Ombretta Colasanti, Zhijian Li, Bo Qin, Meitian Wang, Volker Lohmann, Sheng Cui
The HAV nonstructural protein 2C is essential for virus replication; however, its precise function remains elusive. Although HAV 2C shares 24-27% sequence identity with other 2Cs, key motifs are conserved. Here, we demonstrate that HAV 2C is an ATPase but lacking helicase activity. We identified an ATPase-independent nuclease activity of HAV 2C with a preference for polyuridylic single-stranded RNAs. We determined the crystal structure of an HAV 2C fragment to 2.2 Å resolution, containing an ATPase domain, a region equivalent to enterovirus 2C zinc-finger (ZFER) and a C-terminal amphipathic helix (PBD)...
August 10, 2022: Nucleic Acids Research
https://read.qxmd.com/read/35921698/a-simple-and-sensitive-hplc-fl-method-for-bioanalysis-of-velpatasvir-a-novel-hepatitis-c-virus-ns5a-inhibitor-in-rat-plasma-investigation-of-factors-determining-its-oral-bioavailability
#33
JOURNAL ARTICLE
Eugene Choi, Dong-Gyun Han, Jeong-Eun Park, Ha-Yeon Lee, Jin-Wook Yoo, Yunjin Jung, Im-Sook Song, In-Soo Yoon
Velpatasvir is a novel inhibitor of hepatitis C virus nonstructural protein 5A that received US Food and Drug Administration approval for the treatment of patients with chronic hepatitis C virus genotypes 1-6. In the present study, a sensitive bioanalytical method for velpatasvir was developed using high-performance liquid chromatography coupled with a fluorescence detector system, which was applied to elucidate the factors determining the oral bioavailability and disposition of velpatasvir. This method offered sufficient sensitivity, with a lower limit of quantification of 0...
July 28, 2022: Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
https://read.qxmd.com/read/35891381/an-equine-model-for-vaccination-against-a-hepacivirus-insights-into-host-responses-to-e2-recombinant-protein-vaccination-and-subsequent-equine-hepacivirus-inoculation
#34
JOURNAL ARTICLE
Marcha Badenhorst, Armin Saalmüller, Janet M Daly, Reinhard Ertl, Maria Stadler, Christina Puff, Madeleine de le Roi, Wolfgang Baumgärtner, Michael Engelmann, Sabine Brandner, Hannah K Junge, Barbara Pratscher, Asisa Volz, Bertrand Saunier, Thomas Krey, Johannes Wittmann, Steffen Heelemann, Julien Delarocque, Bettina Wagner, Daniel Todt, Eike Steinmann, Jessika-M V Cavalleri
Equine hepacivirus (EqHV) is the closest known genetic homologue of hepatitis C virus. An effective prophylactic vaccine is currently not available for either of these hepaciviruses. The equine as potential surrogate model for hepacivirus vaccine studies was investigated, while equine host responses following vaccination with EqHV E2 recombinant protein and subsequent EqHV inoculation were elucidated. Four ponies received prime and booster vaccinations (recombinant protein, adjuvant) four weeks apart (day -55 and -27)...
June 27, 2022: Viruses
https://read.qxmd.com/read/35868125/small-molecule-ns5b-rdrp-non-nucleoside-inhibitors-for-the-treatment-of-hcv-infection-a-medicinal-chemistry-perspective
#35
REVIEW
Zhilan Zhou, Jifa Zhang, Enda Zhou, Changyu Ren, Jiaxing Wang, Yuxi Wang
Hepatitis C virus (HCV) infection has become a global health problem with enormous risks. Nonstructural protein 5B (NS5B) RNA-dependent RNA polymerase (RdRp) is a component of HCV, which can promote the formation of the viral RNA replication complex and is also an essential part of the replication complex itself. It plays a vital role in the synthesis of the positive and negative strands of HCV RNA. Therefore, the development of small-molecule inhibitors targeting NS5B RdRp is of great value for treating HCV infection-related diseases...
July 8, 2022: European Journal of Medicinal Chemistry
https://read.qxmd.com/read/35764239/immunogenicity-against-hepatitis-c-virus-with-mesenchymal-stem-cells-of-inbreed-balb-c-mice-sub-cloned-with-hcvcp-protein-gene
#36
JOURNAL ARTICLE
Mahmood Reza Masoudi, Alireza Rafati
BACKGROUND AND AIM: Hepatitis C is one of the leading causes of liver disease in the world and despite extensive research, there is still no vaccine against it. Researchers have identified cell-based therapies as an alternative strategy in advanced liver disorders. The aim of this study was to transfer the hepatitis C virus core protein (HCVcp) gene into mesenchymal stem cells and to evaluate its immunogenicity after injection into mice. MATERIALS AND METHODS: The present study had two experimental and animal stages...
June 25, 2022: Transplant Immunology
https://read.qxmd.com/read/35763545/a-hepatitis-c-virus-genotype-1b-post-transplant-isolate-with-high-replication-efficiency-in-cell-culture-and-its-adaptation-to-infectious-virus-production-in-vitro-and-in-vivo
#37
JOURNAL ARTICLE
Christian Heuss, Paul Rothhaar, Rani Burm, Ji-Young Lee, Philipp Ralfs, Uta Haselmann, Luisa J Ströh, Ombretta Colasanti, Cong Si Tran, Noemi Schäfer, Paul Schnitzler, Uta Merle, Ralf Bartenschlager, Arvind H Patel, Frederik Graw, Thomas Krey, Vibor Laketa, Philip Meuleman, Volker Lohmann
Hepatitis C virus (HCV) is highly diverse and grouped into eight genotypes (gts). Infectious cell culture models are limited to a few subtypes and isolates, hampering the development of prophylactic vaccines. A consensus gt1b genome (termed GLT1) was generated from an HCV infected liver-transplanted patient. GLT1 replicated to an outstanding efficiency in Huh7 cells upon SEC14L2 expression, by use of replication enhancing mutations or with a previously developed inhibitor-based regimen. RNA replication levels almost reached JFH-1, but full-length genomes failed to produce detectable amounts of infectious virus...
June 28, 2022: PLoS Pathogens
https://read.qxmd.com/read/35631457/design-and-synthesis-of-novel-bis-imidazolyl-phenyl-butadiyne-derivatives-as-hcv-ns5a-inhibitors
#38
JOURNAL ARTICLE
Jehad Hamdy, Nouran Emadeldin, Mostafa M Hamed, Efseveia Frakolaki, Sotirios Katsamakas, Niki Vassilaki, Grigoris Zoidis, Anna K H Hirsch, Mohammad Abdel-Halim, Ashraf H Abadi
In today's global plan to completely eradicate hepatitis C virus (HCV), the essential list of medications used for HCV treatment are direct-acting antivirals (DAAs), as interferon-sparing regimens have become the standard-of-care (SOC) treatment. HCV nonstructural protein 5A (NS5A) inhibitors are a very common component of these regimens. Food and Drug Administration (FDA)-approved NS5A inhibitors, although very potent, do not have the same potency against all eight genotypes of HCV. Therefore, this study aims to synthesize NS5A inhibitor analogues with high potency pan-genotypic activity and high metabolic stability...
May 20, 2022: Pharmaceuticals
https://read.qxmd.com/read/35583066/-detection-of-serum-anti-ns2-antibody-and-recombinant-hepatitis-c-virus-nonstructural-protein-2-ns2-its-development-and-evaluation
#39
JOURNAL ARTICLE
Yu Yu, Jun Cheng, Yuzhu Dai, Chuanzhong Mei
Objective To express the recombinant HCV NS2, establish and evaluate the detection method of serum anti-ns2 antibody based on chemiluminescence. Methods Using the NS2 sequence plasmid of HCV 1b genotype (PUC-NS2) as the template, a recombinant plasmid containing the whole NS2 sequence (pGEX-KG-NS2) was constructed. Prokaryotic expression of NS2 protein was induced. The purified NS2 fusion protein was coated on the microplate, and the anti-NS2 antibody detection kit was prepared based on chemiluminescence, and the methodological index was evaluated...
April 2022: Xi Bao Yu Fen Zi Mian Yi Xue za Zhi, Chinese Journal of Cellular and Molecular Immunology
https://read.qxmd.com/read/35566079/monte-carlo-method-and-ga-mlr-based-qsar-modeling-of-ns5a-inhibitors-against-the-hepatitis-c-virus
#40
JOURNAL ARTICLE
Wissal Liman, Mehdi Oubahmane, Ismail Hdoufane, Imane Bjij, Didier Villemin, Rachid Daoud, Driss Cherqaoui, Achraf El Allali
Hepatitis C virus (HCV) is a serious disease that threatens human health. Despite consistent efforts to inhibit the virus, it has infected more than 58 million people, with 300,000 deaths per year. The HCV nonstructural protein NS5A plays a critical role in the viral life cycle, as it is a major contributor to the viral replication and assembly processes. Therefore, its importance is evident in all currently approved HCV combination treatments. The present study identifies new potential compounds for possible medical use against HCV using the quantitative structure-activity relationship (QSAR)...
April 23, 2022: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
keyword
keyword
52719
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.